Roche Gets Positive CHMP Review for Tarceva as First-line Treatment in EGFR-mutated NSCLC

Following a positive recommendation from the EMA committee, the European Commission is expected to issue a decision in September regarding marketing Tarceva as a first-line treatment for EGFR-mutation-positive NSCLC.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.